Therapies

Business Development Manager, Europe - Invetech - San Diego, CA

27 minutes ago | San Diego Biotechnology

Selling a combination of consulting services and technical product solutions in biotech, cell and gene therapy markets. Global VP Commercial .From Fortive - Tue, 10 Dec 2019...
Read more ...

Predicting effective drug combinations using gradient tree boosting based on features extracted from drug-protein heterogeneous network

47 minutes ago | BMC Bioinformatics

Although targeted drugs have contributed to impressive advances in the treatment of cancer patients, their clinical benefits on tumor therapies are greatly limited due to...
Read more ...

KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test

4 hours ago | Xconomy

A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat...
Read more ...

Fate Therapeutics: Senior Process Development Engineer

4 hours ago | San Diego Biotechnology | 3 articles

Fate Therapeutics: seeks experienced, motivated cell therapy process development engineer to lead scale-up and cGMP-compliant PD for new cellular immunotherapeutics 92121, San...
Read more ...

Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer

8 hours ago | Xconomy

The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other...
Read more ...

AveXis Inc.: Research Associate II, Histologist

13 hours ago | San Diego Biotechnology | 3 articles

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego...
Read more ...

AveXis Inc.: Senior Scientist, Analytical Chemistry

13 hours ago | San Diego Biotechnology | 3 articles

AveXis Inc.: OverviewReady to join a team committed to moving gene therapies into the clinical and commercial settings for patients and families devastated by rare San Diego...
Read more ...

Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego's Synthorx

19 hours ago | Xconomy

Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions...
Read more ...

Predicting effective drug combinations using gradient tree boosting based on features extracted from drug-protein heterogeneous network

1 day ago | Springer | 2 articles

Abstract Background Although targeted drugs have contributed to impressive advances in the treatment of cancer patients, their clinical benefits on tumor therapies are greatly...
Read more ...

Editorial focus: understanding off-target effects as the key to successful RNAi therapy

1 day ago | Springer | 2 articles

Abstract With the first RNA interference drug ) on the market, we witness the RNAi therapy field reaching a critical turning point, when further improvements in drug candidate...
Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Perceptive Unveils New $200M Fund to Invest in Early-Stage Biotechs

Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at... Read more ...

Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule

Merck is acquiring cancer drug developer ArQule for $2.7 billion , a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug... Read more ...

KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test

A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat... Read more ...

Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules

Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the... Read more ...

Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer

The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other... Read more ...

Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego's Synthorx

Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions... Read more ...

Artificial Pancreas Keeps Patients Healthier: A Perspective

The late Mayo endocrinologists Russell Wilder, M.D., and Randall Sprague, M.D., would be smiling today at the news for patients with diabetes. Much of their lives and careers... Read more ...

Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals

Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3... Read more ...

AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets

After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and... Read more ...

Alzheimer's drug candidates reverse broader aging, study shows

LA JOLLA-In mouse models of Alzheimer's disease, the investigational drug candidates known as CMS121 and J147 improve memory and slow the degeneration of brain cells. Now, Salk... Read more ...